Aribio announced on the 4th that its hyaluronic acid (HA) filler, developed using proprietary technology, has been approved by the Korea Ministry of Food and Drug Safety. The product is planned to be launched under the brands Bidan and Curea.
In addition to its degenerative brain disease pipeline, including the oral dementia treatment AR1001 currently undergoing global Phase 3 clinical trials, Aribio has established a biomedical team to pursue research and development (R&D) targeting the anti-aging market and has been advancing filler development. Through this, the company secured precise control and purification technology related to HA (PCRT) and confirmed safety and efficacy through human clinical trials conducted by Professor Chang-Hoon Heo’s dermatology team at Seoul National University Bundang Hospital. They emphasized that the clinical trial demonstrated superior effects compared to filler products previously recognized as top-tier in the market.
Aribio plans to obtain European CE certification by the end of next year to grow Bidan and Curea into global brands. To this end, they have also established their own manufacturing facilities that have received Good Manufacturing Practice (GMP) and international standard certifications.
The Aribio biomedical research team stated, "Following the successful development of high value-added fillers, we are also achieving results in R&D using new materials," adding, "We aim to achieve annual sales of 30 billion KRW through domestic sales and exports to China, Southeast Asia, and South America, actively supporting Aribio’s global innovative drug development."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
